"The gadolinium-based contrast agents (GBCAs), which are intravenous drugs used to help make diagnostic tests such as MRI scans or angiography easier to read, can cause a rare and potentially fatal condition known as nephrogenic systemic fibrosis in kidney disease patients, the FDA said."